Develops targeted radiopharmaceuticals and peptide technologies for oncology – from hit identification to early clinical development.
3B Pharmaceuticals GmbH
Berlin-AdlershofNew on Amplifa
About 3B Pharmaceuticals
3B Pharmaceuticals GmbH (3BP) is a private biotechnology company based in Berlin that develops targeted radiopharmaceuticals and diagnostics for oncological indications with high unmet medical need. The company has a peptide discovery and optimization technology platform that spans from hit identification to early clinical development. In addition to developing therapeutic and diagnostic agents (theragnostics), 3BP offers PurAffin®, chemically stabilized peptide ligands and affinity chromatography resins for downstream processing (DSP), as well as the EScalate Equilibrium Shift Assay for determining plasma protein binding. The company was founded in 2008 by experts in peptide drug discovery and nuclear medicine from Berlin, Bern and Basel. In 2022, Novartis licensed 3BP's FAP-targeted peptide technology (FAP-2286). The company is located at the Science and Technology Campus Berlin Adlershof.
- Site
- Berlin
- Processes
- Peptide discovery and optimization, Development of targeted radiopharmaceuticals (therapy and diagnostics/theragnostics), Early clinical development, Custom PurAffin ligands and affinity chromatography resins (DSP), Plasma Protein Binding Assays (EScalate Equilibrium Shift Assay), Licensing of peptide technologies
- Materials
- PurAffin® Peptide Ligands, EScalate Equilibrium Shift Assay, FAP-targeted Peptide Technology
- Founded
- 2008
- Industries
- Biotechnology, Pharmaceutical Industry, Nuclear Medicine/Radiopharmaceuticals, Oncology
- 01
Peptide discovery
- 02
Peptide/peptidomimetic optimization
- 03
Development of targeted radiopharmaceuticals
- 04
Early clinical development
- 05
Licensing of the peptide technology
Technologies & Processes
PurAffin® Peptide Ligands
Chemically stabilized peptidomimetics for affinity chromatography resins in protein purification (DSP), synthetically producible in large quantities.
EScalate Equilibrium Shift Assay
Assay for determining the plasma protein binding of pharmaceutical agents.
FAP-targeted Peptide Technology
Peptide technology for targeted radiopharmaceuticals, licensed by Novartis in 2022.
Locations
Berlin-Adlershof
DEHeadquarters, research & development
Products & Services
Inside the production
Industries
Additional services
Reference customers
History
- 2008
Founded by a team of experts in peptide drug discovery and nuclear medicine from Berlin, Bern and Basel.
- 2022
Novartis consent to the acquisition of FAP-2286 rights from Clovis Oncology; license agreement with Novartis for the FAP-targeted peptide technology (December 2022).